Charles Schwab
TMDX icon

Charles Schwab’s Transmedics TMDX Stock Holding History

Charles Schwab’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.8M Buy
328,666
+9,740
+3% +$824K ﹤0.01% 1779
2026
Q1 		$31.7M Sell
318,926
-4,100
-1% -$535K ﹤0.01% 1469
2025
Q4 		$39.3M Buy
323,026
+2,239
+0.7% +$281K 0.01% 1306
2025
Q3 		$36M Buy
320,787
+5,657
+2% +$662K 0.01% 1361
2025
Q2 		$42.2M Buy
315,130
+10,763
+4% +$1.18M 0.01% 1199
2025
Q1 		$20.5M Buy
304,367
+6,934
+2% +$477K ﹤0.01% 1630
2024
Q4 		$18.5M Buy
297,433
+25,739
+9% +$2.4M ﹤0.01% 1742
2024
Q3 		$42.7M Buy
271,694
+6,634
+3% +$1.02M 0.01% 1230
2024
Q2 		$39.9M Buy
265,060
+7,736
+3% +$928K 0.01% 1224
2024
Q1 		$19M Buy
257,324
+3,807
+2% +$314K ﹤0.01% 1643
2023
Q4 		$20M Buy
253,517
+4,343
+2% +$262K 0.01% 1596
2023
Q3 		$13.6M Buy
249,174
+8,176
+3% +$589K ﹤0.01% 1740
2023
Q2 		$20.2M Buy
240,998
+7,334
+3% +$561K 0.01% 1496
2023
Q1 		$17.7M Buy
233,664
+111
+0% +$7.68K 0.01% 1562
2022
Q4 		$14.4M Buy
233,553
+7,540
+3% +$401K ﹤0.01% 1653
2022
Q3 		$9.43M Buy
226,013
+31,708
+16% +$1.38M ﹤0.01% 1874
2022
Q2 		$6.11M Sell
194,305
-6,548
-3% -$175K ﹤0.01% 2103
2022
Q1 		$5.41M Buy
200,853
+8,121
+4% +$145K ﹤0.01% 2241
2021
Q4 		$3.69M Buy
192,732
+3,799
+2% +$95.2K ﹤0.01% 2501
2021
Q3 		$6.25M Buy
188,933
+16,785
+10% +$513K ﹤0.01% 2266
2021
Q2 		$5.71M Buy
172,148
+5,845
+4% +$162K ﹤0.01% 2280
2021
Q1 		$6.9M Buy
166,303
+6,606
+4% +$203K ﹤0.01% 2140
2020
Q4 		$3.18M Sell
159,697
-774
-0.5% -$11.5K ﹤0.01% 2445
2020
Q3 		$2.21M Buy
160,471
+87,548
+120% +$1.5M ﹤0.01% 2458
2020
Q2 		$1.31M Buy
72,923
+19,429
+36% +$304K ﹤0.01% 2553
2020
Q1 		$647K Buy
53,494
+536
+1% +$8.98K ﹤0.01% 2622
2019
Q4 		$1.01M Buy
52,958
+13,068
+33% +$240K ﹤0.01% 2595
2019
Q3 		$948K Buy
39,890
+1,993
+5% +$47.8K ﹤0.01% 2585
2019
Q2 		$1.1M Buy
+37,897
New +$1.03M ﹤0.01% 2548

Other funds holding TMDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Charles Schwab's TMDX Position: Q2 2026 in Review

Charles Schwab increased its Transmedics (TMDX) stake by 3.1% in Q2 2026, buying an estimated $824K and bringing the position to 328,666 shares worth $21.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1779.

Charles Schwab first reported a position in TMDX in Q2 2019 and has held it in 29 quarters since. The position peaked at $42.7M in Q3 2024. 373 funds tracked by Wall St. Rank hold TMDX as of Q2 2026.

  • Charles Schwab held 328,666 shares of Transmedics worth $21.8M as of Q2 2026.
  • Charles Schwab bought 9,740 Transmedics shares in Q2 2026, an estimated $824K.
  • Transmedics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1779 holding.
  • Charles Schwab first reported a position in Transmedics in Q2 2019 and has held it in 29 quarters since.
  • Charles Schwab's Transmedics position peaked at $42.7M in Q3 2024.
  • 373 funds tracked by Wall St. Rank held Transmedics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.